Delcath Systems Stock News

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today anno

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announ

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announ

Overall Response Rate of 72% observed in patients with metastases confined to the liver Overall Response Rate of 72% observed in patients with metastases confined to the liver

Zacks Investment Research upgraded shares of Delcath Systems (OTCMKTS:DCTH) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Delca

Safety data of early part of FOCUS trial have been publicly disseminated. Early data of FOCUS trial show a vastly improved safety profile of Chemosat.

The following slide deck was published by Delcath Systems, Inc. in conjunction with this event..

Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2020 Results Earnings Conference Call August 13, 2020, 04:30 PM ET Company Participants James Carbonara - Hayden IR John Purpura - Interim Chief Executive Office

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, annou

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a